Canagliflozin (ITP longevity)

Estimated longevity benefit: +1.0 years. Evidence score: 60/100.

Overview

Canagliflozin is an SGLT2 inhibitor that promotes the excretion of glucose through the urine to lower blood sugar and insulin levels. This metabolic shift induces a state of caloric restriction mimicry that has demonstrated significant and reproducible lifespan extension in male animal models.

Evidence assessment

Canagliflozin belongs to the SGLT2 inhibitor class — drugs that block the sodium-glucose cotransporter-2 protein in kidney tubules, causing glucose to be excreted in the urine rather than reabsorbed into the bloodstream. Originally developed for type 2 diabetes, SGLT2 inhibitors (including empagliflozin, dapagliflozin) have demonstrated cardiovascular and renal benefits in landmark trials (EMPA-REG OUTCOME, CANVAS, CREDENCE) that were unexpected for diabetes drugs and point to mechanisms beyond glucose lowering.

The primary mechanism involves the induction of a state of "metabolic caloric restriction mimicry" through continuous urinary glucose loss, which activates AMPK and promotes fat oxidation. This metabolic shift is believed to be the driver behind the robust 14% median lifespan extension observed in male mice across multiple ITP cohorts, even when treatment was started late in life. By forcing the body to rely more on fat stores for energy and reducing systemic insulin levels, canagliflozin addresses the metabolic dysregulation that is a hallmark of the aging process. This systemic reprogramming essentially "tricks" the body into a longevity-promoting state similar to long-term caloric restriction, without the associated nutritional deficiencies.

The ITP Finding: Miller et al. (2020) in *JCI Insight* and Harrison et al. (2024) in *GeroScience*: - +14% median lifespan in males at 180 ppm, started at 7 months - +9% maximum lifespan in males — longevity benefit extends to the longest-lived animals - Late start (16 months): Still +13.8% in males — the effect holds even at older ages - Females: No benefit in young-start cohort - Critical finding: Aged females showed -6.1% lifespan REDUCTION in the late-start cohort - Blood levels of canagliflozin were 20-fold higher in aged females vs. aged males — suggesting age-sex-specific pharmacokinetics that may drive toxicity

The Sex-Specific Pharmacology Warning: This is the most important cautionary finding in the ITP's 20-year history: the same drug that extends male lifespan may reduce female lifespan. The mechanism likely involves dramatically higher blood concentrations in aged females — either from reduced clearance or altered distribution. This is not a minor statistical noise; it's a consistent finding that has major implications for any extrapolation to human use.

Mechanisms of Male Lifespan Extension: 1. Metabolic caloric restriction mimicry: Urinary glucose loss (~70g/day at clinical doses) forces a shift to fat oxidation, activating AMPK and partially mimicking caloric restriction 2. Ketone elevation: SGLT2 inhibition increases blood ketone levels (β-hydroxybutyrate), which has anti-inflammatory, histone deacetylase-inhibiting, and neuroprotective properties 3. Visceral fat reduction: Male mice on canagliflozin show reduced visceral adiposity — removing a primary driver of age-related inflammation 4. Cardiac load reduction: Urinary glucose excretion reduces osmotic and hemodynamic cardiac load, explaining the cardiac benefits seen in human trials 5. Reduced mTORC1 activity: Some evidence that SGLT2 inhibitors modulate mTOR signaling in a direction consistent with longevity benefits

Human Evidence: Multiple large cardiovascular outcome trials (CANVAS, EMPA-REG, CREDENCE, DAPA-HF) have shown SGLT2 inhibitors reduce cardiovascular death and hospitalization in diabetes patients. Whether this reflects a longevity effect or just cardiovascular protection is unclear. The EMPACT-MI and other trials are extending this to non-diabetic populations.

The Bottom Line on Sex: Any longevity consideration of canagliflozin must account for the female toxicity signal. The ITP finding is a warning, not a nuance — aged females had both higher drug exposure AND worse outcomes. This is a case study in why sex-stratified analysis matters.

Implementation protocol

Critical Warning: Canagliflozin is a powerful metabolic modifier that can cause significant shifts in fluid balance and electrolyte levels. It is essential that any use for longevity is monitored by a medical professional to avoid complications such as dehydration or ketoacidosis, particularly during periods of illness or fasting. - Canagliflozin (Invokana) is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease — NOT for longevity - The ITP found canagliflozin may REDUCE lifespan in aged females — this is a critical sex-specific safety signal - Off-label longevity use requires physician supervision; especially caution in women - Contraindicated in: eGFR <30 ml/min/1.73m², end-stage renal disease, dialysis, type 1 diabetes (risk of DKA), recurrent urinary/genital infections

FDA-Approved Dosing (for approved indications): The primary clinical application of canagliflozin is in the management of type 2 diabetes and the reduction of cardiovascular and renal complications. These established doses have been rigorously tested for safety and efficacy in patients with metabolic disease, but their transposition to a general longevity context requires careful individualized adjustment. - Canagliflozin (Invokana): 100–300mg once daily - Other SGLT2 inhibitors: Empagliflozin (Jardiance) 10–25mg, Dapagliflozin (Farxiga) 5–10mg - SGLT2 inhibitors as a class have similar mechanisms — the ITP specifically tested canagliflozin

Monitoring: Regular clinical assessment is required to ensure that the drug's impact on kidney function and systemic glucose remains within safe parameters. Because SGLT2 inhibitors alter the way the body handles fuel, monitoring for rare but serious metabolic complications is a cornerstone of safe administration. - eGFR and creatinine: Essential baseline and ongoing monitoring - HbA1c and fasting glucose: Metabolic benefit confirmation - Urinalysis: Increased glucose in urine predisposes to UTIs and fungal infections (especially in women) - Ketones: Euglycemic DKA is a rare but serious complication, especially in periods of fasting/surgery - Blood pressure: SGLT2 inhibitors have mild antihypertensive effects — may need medication adjustment

Human Cardiovascular Evidence: The translation of SGLT2 inhibitor benefits from animal models to humans is supported by extensive data in populations with metabolic disease. These trials consistently show reduced rates of heart failure and kidney decline, providing a strong rationale for investigating their effects on the fundamental processes of human aging. - CANVAS Trial: Canagliflozin reduced major cardiovascular events by 14% - CREDENCE: Canagliflozin reduced kidney disease progression by 30% in CKD patients - These are meaningful benefits, but these populations are not the general longevity-seeking public

Sex-Specific Note: The biological differences in drug response between sexes are particularly pronounced with SGLT2 inhibitors, as evidenced by the divergent outcomes in preclinical studies. A careful individualized assessment is necessary for female users to ensure that the metabolic gains do not come at the cost of increased systemic risk. Given the ITP female toxicity signal, women without clear indications (diabetes, heart failure, CKD) should be especially cautious about off-label longevity use. The finding that aged female mice had 20-fold higher blood concentrations suggests pharmacokinetic differences that may also exist in older women.

Scientific citations

Expert perspectives

Related interventions